Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults
- 4 January 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (1), e2031266
- https://doi.org/10.1001/jamanetworkopen.2020.31266
Abstract
Older adults are at high risk for severe influenza illness, cardiovascular events, hospitalization, functional decline, and death following influenza infection.1-10 Hospitalization rates for laboratory confirmed influenza are up to 10 times higher in people aged 65 years or older compared with younger adults.1 An estimated 71% to 90% of deaths from influenza occur in adults aged 65 years or older.7,8 The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommends annual vaccination with any US-licensed, age-appropriate, influenza vaccine.11 In the US, influenza vaccines that are licensed for use only in persons aged 65 years and older are trivalent high-dose inactivated influenza vaccine (HD-IIV3 [Fluzone® High-Dose, licensed 2009]12), trivalent adjuvanted inactivated influenza vaccine (aIIV3 [Fluad®, licensed 2015]13), quadrivalent high-dose inactivated influenza vaccine (HD-IIV4 [Fluzone® High-Dose Quadrivalent, licensed 2019]14), and quadrivalent inactivated adjuvanted influenza vaccine (aIIV4 [Fluad® Quadrivalent, licensed 2020]15).This publication has 28 references indexed in Scilit:
- Influenza Infection and Risk of Acute Myocardial Infarction in England and Wales: A CALIBER Self-Controlled Case Series StudyThe Journal of Infectious Diseases, 2012
- Development of the Computer-Adaptive Version of the Late-Life Function and Disability InstrumentThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2012
- Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008Clinical Infectious Diseases, 2012
- Postlicensure Safety Surveillance for High-Dose Trivalent Inactivated Influenza Vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010Clinical Infectious Diseases, 2012
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Stratified Wilson and Newcombe Confidence Intervals for Multiple Binomial ProportionsStatistics in Biopharmaceutical Research, 2010
- Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and OlderThe Journal of Infectious Diseases, 2009
- Influenza- and RSV-associated hospitalizations among adultsVaccine, 2007
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the United StatesJAMA, 2003
- Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaireQuality of Life Research, 1993